Tagworks Pharmaceuticals Email Format

Pharmaceutical ManufacturingGelderland, Netherlands11-50 Employees

Tagworks Pharmaceuticals is a small to mid-sized biopharma company focused on precision oncology. It develops therapies for solid tumors using its proprietary platform to selectively release therapeutic payloads at clinically validated tumor markers that have historically evaded current treatments. The company’s lead program, TGW101, is an antibody-drug conjugate directed at TAG72, a protein expressed on the surface of many solid tumor cells. Tagworks is headquartered in Nijmegen, Gelderland, Netherlands, and maintains operations in the United States.

It is building a pipeline of cancer therapies that span antibody-drug conjugates and targeted radiopharmaceutical therapies. In October 2025, Tagworks announced a collaboration with Radboud University Medical Center to initiate the first-in-human Phase 0/1 development of TGW211 in a single-center, open-label imaging study for patients with HER2-positive solid tumors.

Sign up for free to view info

Company overview Employee directory